Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
Open Access
Abstract
Introduction Chronic hepatitis C virus (HCV) infection rates are high in the geriatric population considering that interferon-based therapy is usually intolerable. With the introduction of oral antiviral therapy for HCV, increased treatment tolerability and good treatment responses have been observed. However, treatment data regarding the geriatric population have been limited. Therefore, this retrospective study aimed to evaluate the efficacy and safety of direct-acting antiviral therapy for HCV in the geriatric population. Materials and Methods The primary end point was sustained virologic response (SVR) 12 weeks after treatment completion, whereas the secondary end points were treatment-related side effects and short-term survival rate following treatment. Results In total, 492 patients (median age, 73 years; 43.9% males), including 278 early elderly patients, were enrolled. Among the included patients, 45% had cirrhosis. HCV genotypes 1 (72.4%) and 2 (25.4%) were the most common. The overall SVR rate was 96.7%, with no difference in SVR rates observed between early and late elderly groups (96.8% vs. 96.7%; p = 0.983). Both groups showed similar side effects, including dizziness (11.4%), and fatigue (8.7%), with three patients discontinuing therapy owing to side effects. Both groups had a similar 3-year survival rate. Significant factors associated with post-treatment survival included cirrhosis, albumin, and creatinine level. Conclusions Our real-world data showed that both early and late elderly patients could undergo direct-acting antiviral treatment for HCV with excellent treatment outcomes.Keywords
Funding Information
- Changhua Christian Hospital (108-CCH-IRP-018, 109-CCH-IRP-008)
This publication has 30 references indexed in Scilit:
- Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or olderHepatology, 2016
- Hepatitis C Cure with Antiviral Therapy – Benefits beyond the LiverAntiviral Therapy, 2016
- Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapyWorld Journal of Gastroenterology, 2014
- Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infectionWorld Journal of Gastroenterology, 2014
- Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving HemodialysisAnnals of Internal Medicine, 2013
- Long‐term outcome of elderly patients (75 years or older) with hepatocellular carcinomaHepatology Research, 2013
- Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2012
- Pruritus in the elderly: clinical approaches to the improvement of quality of life.2012
- Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis CWorld Journal of Gastroenterology, 2012
- Hepatitis C Virus Infection in the ElderlyDrugs & Aging, 2008